Notable
BELLAVISTA · BRX011 Oral Administration Once Daily · Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary completion pushed from Nov 11, 2026 to Apr 2029
Also in this update: Recruitment opened; Trial sites expanded: 0 → 17 locations
Biojiva LLCPhase 1/2 NCT07029945 Registry history of NCT07029945 on ClinicalTrials.gov (opens the registry)
Updated